NatiVita is an international research and manufacturing company developing and producing innovative pharmaceuticals including drugs for lung, breast, pancreas, ovarian, as well as other types of cancer. It is the first company of its kind in Belarus, conducting the production of monoclonal antibody-based biotech drugs and offering treatment solutions for cancer patients. Working hand-in-hand with leading research and development institutions in India, Slovakia, Lithuania, Russia, France and Spain, NatiVita has developed contemporary production process of biotech pharmaceuticals for cancer treatment, as well as other diseases and syndromes. Founded in 2012, NatiVita’s operations currently span over a modern R&D center and state-of-the-art medicine manufacturing center in Vitebsk, Belarus. Company’s partners include investment holding ZIA Valda, Natco Pharma and Invest Pharma.
